logo
July Fourth, measles vaccines and healthy travel: The week in Well+Being

July Fourth, measles vaccines and healthy travel: The week in Well+Being

Washington Post03-07-2025
Looking forward to a holiday weekend? So are we. We're thinking about grilling recipes, sun safety (check out the pros and cons of chemical and mineral sunscreens in this guide), how much we should be concerned about measles while traveling (given we're having the biggest outbreak in years) and the latest must-have gadget for healthy travel. But before that …
You've packed a toothbrush, your sunscreen and a swimsuit for your summer travel. Now, what about a carbon monoxide detector? 'The chances of being poisoned are really low, but they're not zero,' Lindell Weaver, the medical director of hyperbaric medicine at Intermountain Medical Center in Murray, Utah, told our reporter Teddy Amenabar.
Kathryn Gillett, 44, from Wichita, said she bought a battery-powered carbon monoxide detector two years ago for a stay at an apartment in Buenos Aires. Now, she tosses it in her bag every time she travels, she said.
'Why wouldn't you travel with one?' asked Gillett, who said the device is about the size of two smartphones stacked together, weighs 10 ounces and cost her $20.
To find out more about why you might consider adding a carbon monoxide detector to your short list of must-have travel items, read our article here.
For many people who struggle to eat a healthy diet, the biggest barrier is often cost: Nutritious foods such as fruits, vegetables, meat and seafood tend to be a lot more expensive than ultra-processed foods.
But that's not always the case. Some of the most nutritious foods are also among the most affordable: beans, peas and lentils, collectively known as pulses.
Pulses are high in protein and fiber. They promote gut health, help with weight loss, and improve blood sugar and cholesterol levels. Studies have also found that beans, peas and lentils have a low carbon footprint.
To find out more about how beans can make you healthier — and some of the best ways to make them on a budget — read this article from nutrition reporter Anahad O'Connor.
Our guest columnist this week is Christopher W.T. Miller, MD, a psychiatrist and psychoanalyst practicing at the University of Maryland Medical Center and an associate professor at the University of Maryland School of Medicine.
I had a falling out with a decades-old friend, whom I considered family, and now she won't talk to me. I don't know what life is without her in it. What do I do now?
I have been asked variations on this question by numerous people, as they struggled to figure out how to carry on after the end of a relationship. Whether it's a romantic partner, friend or family member, when important people are no longer part of our lives, it can feel as though our center of gravity has been shifted, leaving us aimless and adrift.
When the other is choosing to exclude us from their lives, the grief we experience can be profound, as this carries the painful message that their life is better without us. When a relationship ends, we lose the other person, and how we think of ourselves can be affected, especially if we have come to define ourselves within the context of the relationship.
To find out more about what to do if a friend cuts you off, read the full response here. And if you have a question for a therapist about mental health, relationships, sleep, dating or any other topic, email it to AskATherapist@washpost.com, and we may feature it in a future column.
Here are a few things that brought us joy this week.
Let's keep the conversation going. We want to hear from you! Email us at wellbeing@washpost.com.
Want to know more about 'joy' snacks? Reporter and former neuroscientist Richard Sima explains what they are and how they can make you feel happier. You can also read his advice as a comic.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

CareBand® Secures New U.S. Patent for Tri-Radio Wearable Architecture Enabling "Everywhere" Low-Power Tracking
CareBand® Secures New U.S. Patent for Tri-Radio Wearable Architecture Enabling "Everywhere" Low-Power Tracking

Yahoo

time20 minutes ago

  • Yahoo

CareBand® Secures New U.S. Patent for Tri-Radio Wearable Architecture Enabling "Everywhere" Low-Power Tracking

CHICAGO, July 22, 2025 /PRNewswire/ -- CareBand, Inc. today announced the award of U.S. Patent 12,298,410, "Wireless Devices, Systems and Methods for Long–Range Radio–Frequency Location Tracking of Objects." The patent protects core logic that lets a single wearable roam automatically among Bluetooth® Low Energy (BLE), nationwide low–power wide–area networks (LPWAN), and direct–to–satellite links, all while using very little battery power. With this latest grant, CareBand's portfolio grows to 16 issued patents that stretch back to 2014. Why this matters now Ubiquitous coverage is finally economical. Global LPWAN revenues are projected to top US $48 billion in 2025 and grow 8–fold by 2030 as logistics, healthcare, and utilities connect mobile assets at scale. (Mordor Intelligence) Space becomes the new cell tower. Multiple mobile operators completed direct–to–orbit voice and data trials over the past year, showing that mass–market devices can now reach satellites when terrestrial service disappears. (The Verge) Bluetooth is breaking its 30–foot leash through mesh. With upgrades like BLE Mesh 1.1, swarms of low–power beacons now knit building– to neighborhood–scale coverage without costly gateways. (Electronic Design) "Back in 2014 we set out to build a discreet wearable for people living with dementia. One that could stay connected to a bedside beacon, then hop to a nationwide low–power network and, if needed, straight to space," said Adam Russek–Sobol, founder and CEO of CareBand. "A decade of R&D later, the market has caught up—and this patent secures the hand–off logic that keeps people and assets visible when legacy tags go dark." What the patent covers Tri–radio decision engine that chooses the cheapest, lowest–energy path, BLE indoors, LPWAN in towns, satellite in the wilderness. Adaptive quality–of–service (QoS) and on–device analytics that prioritise critical health or safety data when bandwidth is scarce. Beacon–defined geofences: caregivers or fleet managers drop beacons to set safe zones, no wiring required. Alert feedback loop: haptic, light, or audible cues on the wearable plus real–time alerts to any web–connected dashboard. Collaboration & LicensingCareBand is actively engaging chipset vendors, device makers, and network operators to license the company's tri–radio IP or co–develop next–generation safety wearables and asset tags. To start a conversation, email sales@ About CareBand develops wearables and software that keep vulnerable people safe and connected. Built on a decade of R&D, CareBand's platform delivers real-time location, fall detection, and behavioral insights over the world's lowest-power networks. Media Contact:media@ View original content: SOURCE CareBand, Inc. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Former Sandoz Inc. CEO Don DeGolyer Leads PharmaTech Startup Ategenos as Company Prepares Public Launch
Former Sandoz Inc. CEO Don DeGolyer Leads PharmaTech Startup Ategenos as Company Prepares Public Launch

Yahoo

time20 minutes ago

  • Yahoo

Former Sandoz Inc. CEO Don DeGolyer Leads PharmaTech Startup Ategenos as Company Prepares Public Launch

Veteran pharma operator co-founded Ategenos to tackle the global $1 trillion crisis of medication non-adherence CAMBRIDGE, Mass., July 22, 2025 /PRNewswire/ -- Ategenos, a pharmatech company, today announced that Co-Founder and Chief Executive Officer Don DeGolyer is leading the company as it prepares to exit stealth and unveil its platform addressing one of healthcare's most costly and persistent challenges: medication non-adherence. Logo of Ategenos, a PharmaTech company focused on connected drug delivery Ategenos has been quietly developing a novel platform that integrates pharmaceutical science with real-time digital health technologies to address adherence in critical dose management. The company will share details on its SmartPatch platform and initial partnerships in the coming weeks. "Medication doesn't work if it's not taken. Yet non-adherence remains one of the biggest drivers of avoidable healthcare costs worldwide," said DeGolyer. "From the start, we set out to build a platform that combines drug delivery, actionable real-world data, and caregiver intervention. We provide caregivers the peace of mind that their loved ones have taken their critical dose medicines and are not at risk of a catastrophic health event." Medication non-adherence contributes to an estimated 125,000 preventable deaths and more than $500 billion in avoidable healthcare costs annually in the U.S., with global costs exceeding $1 trillion each year. DeGolyer brings over 40 years of leadership across the pharmaceutical industry. As President & CEO of Sandoz Inc., he grew revenues by $2 billion in four years, building one of the largest generics businesses in North America. As COO of Endo Pharmaceuticals, he helped scale the company from $2 billion to $18 billion in market cap within two years. He also founded and led Vertice Pharmaceuticals, doubling revenue during his tenure and building a platform that later contributed to a $700 million strategic sale. Don has held senior roles at Pfizer, Johnson & Johnson, and Novartis, advisory positions with Koch Investment Group and Formation Bio, and serves on the board of Emergent BioSolutions. DeGolyer has built a founding team combining pharma leadership, MIT-rooted technology innovation, and venture capital expertise. With experience spanning drug delivery, IoT, real-world data, and company building, Ategenos is uniquely positioned to operate at the intersection of pharmaceuticals and technology. About Ategenos Ategenos is a Massachusetts-based PharmaTech company improving quality of life for patients and their families with its SmartPatch platform—an advanced transdermal system that combines sustained drug delivery with real-time monitoring and caregiver interventions. The technology reduces health risks, hospitalizations, and the $1T+ global costs caused by missed doses of critical medications. The company's founders uniquely combine global pharma leadership, MIT-driven technology, and a proven track record of building and scaling healthcare platforms.

Danaher Lifts 2025 Earnings Outlook Amid Biotech Growth, Cost Discipline
Danaher Lifts 2025 Earnings Outlook Amid Biotech Growth, Cost Discipline

Yahoo

time20 minutes ago

  • Yahoo

Danaher Lifts 2025 Earnings Outlook Amid Biotech Growth, Cost Discipline

Danaher Corp (NYSE:DHR) on Tuesday reported second-quarter 2025 sales of $5.94 billion, up 3.5% year-over-year, beating the consensus of $5.84 billion. The life science giant reported adjusted earnings of $1.80 per share, beating the consensus of $1.64. Non-GAAP core revenue increased 1.5% year over year, compared to the expectations of a growth in low single digits year over year. Operating cash flow was $1.3 billion, and non-GAAP free cash flow was $1.1 billion. Danaher's second-quarter adjusted operating profit margin of 27.3% exceeded expectations of around 25.5%.Biotechnology sales increased to $1.85 billion compared to $1.71 billion a year ago, with core growth of 6%. Sales in the Life Sciences segment remained flat at $1.78 billion, and diagnostic sales increased from $2.26 billion to $2.31 billion. The company said, "DBS-driven execution, paired with another quarter of +HSD growth in Bioprocessing and disciplined cost management, enabled us to exceed our Q2 adjusted EPS and cash flow expectations." Guidance Danaher raised fiscal 2025 adjusted earnings guidance from $7.60-$7.75 per share to $7.70-$7.80, compared to the consensus of $7.70. The company cites good traction on cost initiatives. View more earnings on DHR Danaher reaffirms that in fiscal year 2025, non-GAAP core revenue will grow by approximately 3% year over year. Cepheid 2025 respiratory revenues will be around $1.7 billion. The company expects an adjusted operating profit margin of around 25.5%. Biotechnology core revenue growth is expected to be approximately 6% for the third quarter of 2025 and around 7% for the fiscal year 2025. Life sciences core revenue will remain flat for the third quarter and fiscal year 2025. Diagnostics sales are expected to increase in the low single digits in the third quarter and flat to low single digits in fiscal year 2025. Management update Danaher announced Matthew Gugino, currently group CFO of Life Sciences Innovations Group and VP of Financial Planning & Analysis, will succeed Matthew McGrew as Danaher's CFO, effective February 28, 2026. Analyst Opinion William Blair writes that the macro backdrop for life science tools and bioprocessing companies was anything but sanguine in the second quarter, with escalating concerns surrounding the funding environment, tariffs, MFN, and whether these uncertainties resulted in a slowdown in the overall demand environment." Danaher's results suggest that was not the case, at least in the second quarter, particularly within bioprocessing. Analyst Matt Larew maintains the Outperform rating. Price Action: DHR stock is trading 0.68% higher at $189.34 at the last check on Tuesday. Read Next:Photo via Shutterstock Latest Ratings for DHR Date Firm Action From To Jan 2022 Wells Fargo Maintains Overweight Jan 2022 Barclays Maintains Overweight Jan 2022 Bernstein Initiates Coverage On Outperform View More Analyst Ratings for DHR View the Latest Analyst Ratings UNLOCKED: 5 NEW TRADES EVERY WEEK. Click now to get top trade ideas daily, plus unlimited access to cutting-edge tools and strategies to gain an edge in the markets. Get the latest stock analysis from Benzinga? DANAHER (DHR): Free Stock Analysis Report This article Danaher Lifts 2025 Earnings Outlook Amid Biotech Growth, Cost Discipline originally appeared on © 2025 Benzinga does not provide investment advice. All rights reserved. Errore nel recupero dei dati Effettua l'accesso per consultare il tuo portafoglio Errore nel recupero dei dati Errore nel recupero dei dati Errore nel recupero dei dati Errore nel recupero dei dati

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store